Journal Article (Letter)

DKFZ-2021-02422

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.

Leypoldt, L. B. ; Besemer, B. ; Asemissen, A. M. ; Hänel, M. ; Blau, I. W. ; Görner, M. ; Ko, Y.-D. ; Reinhardt, H. C.DKFZ* ; Staib, P. ; Mann, C. ; Lutz, R. ; Munder, M. ; Graeven, U. ; Peceny, R. ; Salwender, H. ; Jauch, A. ; Zago, M. ; Benner, A.DKFZ* ; Tichy, D.DKFZ* ; Bokemeyer, C. ; Goldschmidt, H. ; Weisel, K. C.

2022
Springer Nature London

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41375-021-01431-x

Note: 36, pages 885–888 (2022)

---

Contributing Institute(s):

1. DKTK ED ES zentral (ED01)
2. C060 Biostatistik (C060)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2021

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---